Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® EP Attends the 10th VAS-CHINA


Nanjing, China – The Columbus™ 3D EP Navigation System ("Columbus™") that developed by Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") impressed attendees of the 10th Ventricular Arrhythmia Symposium ("VAS-CHINA") in Nanjing, Jiangsu Province with its outstanding performance in tackling ventricular arrhythmias.
Columbus™ was well recognized by the conference moderator Professor Minglong Chen of Jiangsu Province Hospital & the first affiliated hospital with Nanjing Medical University for its stability and outstanding performance when compared with imported 3D systems at the stage.
It also won positive feedback from Professor Wenqing Zhu and Professor Kuan Chen of Zhongshan Hospital affiliated to Fudan University. They presented the use of Columbus™ to treat frequent premature ventricular contraction at the VAS-CHINA. Professor Zhu found the earliest sites in the RCC and measured successful ablation after mapping in the RA, LV and aortic sinus.
A seminar titled "Columbus™: Navigation for the Heart" was chaired by Professor Lianjun Gao of the First Hospital affiliated to Dalian Medical University during the conference period. Professor Feng Ze of Peking University People's Hospital gave full credit to Columbus™ in providing guidance to clinical practice with its characteristics of accurate measurement, accurate positioning and easy to interpret. He shared his experience in using Columbus™ system to complete two rare cases of atrial tachycardia originated from atrial septal and pulmonary vein. Professor Chaoqun Zhang of the Affiliated Hospital of Xuzhou Medical University reported on the case of Electrocardiogram features and ablation procedure of outflow tract ventricular premature beat. At the end of the seminar, Professor Xiaomeng Yi with the First Hospital Affiliated to Dalian Medical University suggested not to give up catheter ablation when sharing his experience in choosing between ICD and radiofrequency ablation for organic ventricular arrhythmias. Yi mentioned one patient who refused ICD implantation eventually stopped ventricular tachycardia attack by repeatedly catheter ablation. Gao ended the seminar by saying that the launch of Columbus™ had far-reaching influence on the domestic EP industry.
Ventricular arrhythmia is a common arrhythmia. Ventricular tachycardia, flutter and fibrillation are the main causes of sudden cardiac death. Effective prevention of ventricular arrhythmia has great clinical significance in preventing sudden cardiac death. Columbus™ is the first domestically developed 3D EP navigation system that features real time electromagnetic device tracking with cardiac motion compensation. It is also the only domestically made 3D EP navigation system with the CE certificate, which has won high recognition from domestic experts for its outstanding performance. As the only domestic company that provides a complete solution of cardiac EP treatment, MicroPort® EP will continue to strive for innovation and perfection to provide better arrhythmia solutions for patients and physicians.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:Foxtrot™ NC PTCA Gains Regulatory Approval in Malaysia
[Next]:Tubridge® Gains CFDA Approval